cas 76536-66-8|| where to buy 9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Nombre del producto:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

IUPAC Name:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Unidad de embalaje	Stock disponible	Precio($)	Cantidad

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 76536-66-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :76536-66-8; Fórmula molecular:C23H25N3O3; Punto de fusión:-; Código de sonrisas:COC1=CC2=C(C=C1OC)C1=CC(NC3=C(C)C=C(C)C=C3C)=NC(=O)N1CC2; Densidad:

: Número de catálogo:CM1045836; Peso molecular:391.47; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Ensifentrine; Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).